FindTrial
Sign In

Circulating tumor DNA (ctDNA) analyses as a predictive marker for cancer treatment in solid tumors

Circulating tumor DNA (ctDNA) analyses as a predictive marker for cancer treatment in solid tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008188
Enrollment
100
Registered
2023-02-14
Start date
2023-01-03
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Chonnam National University Hospital Hwasun Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male and female participants >=18 years of age inclusive, at the time of signing the informed consent Histologically confirmed metastatic solid cancer Participants with accessible tumor will undergo a pre-treatment Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 after operation, radiotherapy or chemotherapy Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Agreement to donate blood sample (20ml) during the study period Ability to comply with the study protocol in the investigator's judgement

Exclusion criteria

Exclusion criteria: Histologically who are not confirmed with solid cancer Amount of sample that can not be analyzed

Design outcomes

Primary

MeasureTime frame
circulating tumor DNA—

Secondary

MeasureTime frame
Progression free survival, Overall survival—

Countries

Korea, Republic of

Contacts

Public ContactHyun Jin Bang

Chonnam National University Hospital Hwasun Hospital

daunjin@gmail.com+82-61-379-7626

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026